Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment (clinicaltrials.gov) - Sep 23, 2026 - P3 | N=428 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Trial primary completion date: Sep 2026 ➔ Dec 2026
Trial primary completion date • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HER-2
|